Results 141 to 150 of about 4,912,345 (213)

Diagnosis and Medication Treatment of Schizophrenia in Adolescents. [PDF]

Drugs
Findling RL, Shah D, Prajapati P, Cordrey E, Nichols M, Stepanova E.   +5 more
europepmc   +1 more source

Dopaminergic hypersensitivity of the opioid-responsive striatal-entopeduncular pathway in a rodent model of restless legs syndrome. [PDF]

Neuropsychopharmacology
Valle-León M, Rea W, Quiroz C, Sánchez WN, Albornoz S, Rule AM, Cai NS, Ciruela F, Earley CJ, Ferré S.   +9 more
europepmc   +1 more source

Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved Drugs. [PDF]

ACS Pharmacol Transl Sci
Racz R, Kozell LB, Eshleman AJ, Bloom SH, Wolfrum KM, Schmachtenberg JL, Swanson TL, Ngai J, Schutzer WE, Janowsky A, Abbas AI, Stavitskaya L.   +11 more
europepmc   +1 more source

Strategic Timing of Resistance Training to Guard Against Antipsychotic-Induced Metabolic Syndrome (START GAAIMS): A Feasibility Study Protocol. [PDF]

HRB Open Res
O'Mahony B, Pumpa K, O'Shea D, O'Connor K, Norton M, O'Donoghue B.   +5 more
europepmc   +1 more source

Secondary Restless Legs Syndrome during psychopharmacological treatment: real-world evidence from a multinational pharmacovigilance program. [PDF]

Int J Neuropsychopharmacol
Fugger G, Rabl U, Bartova L, Popper V, Watzal V, Ivkic D, Donath J, Busvine C, Greil W, Toto S, Grohmann R, Frey R, Konstantinidis A, Erfurth A, Kasper S.   +14 more
europepmc   +1 more source

Restless revelations - Unveiling Uncommon Occurrence of Cariprazine-Induced Akathisia. [PDF]

Ind Psychiatry J
Nandish M, Agrawal M, Chauhan VS.
europepmc   +1 more source

Predictors of extrapyramidal side effects among patients taking antipsychotic medication at Mekelle psychiatry units, Northern Ethiopia, 2023: unmatched case-control study. [PDF]

BMC Psychiatry
Gebru WA, Asfaw GK, Berhe KT, Begashaw TD, Reta HG, Gebresilassie HT.   +5 more
europepmc   +1 more source

Metoclopramide-induced acute dystonia in an adolescent. [PDF]

Indian J Pharmacol
Kumar KJ, Kundur S, Bulusu LV, Nandish HR, Mehta P.   +4 more
europepmc   +1 more source

SOM3355: a unique pharmacological profile combining VMAT1 inhibition, VMAT2-mediated dopamine modulation, and β₁-adrenergic antagonism for the treatment of movement and neuropsychiatric disorders. [PDF]

Front Pharmacol
Turilli-Ghisolfi ES, Støve SI, Huertas O, Kråkenes TA, Teigen K, Panigone S, Medori R.   +6 more
europepmc   +1 more source